IBD Stress Test
最高50,000美元的赠款+ Access to mentorship
优胜者
The University of Oxford
TheTranslational Gastroenterology Unit(TGU) at the University of Oxford aims to blend basic science with clinical studies to improve care, find the cause, and develop a cure for diseases of the GI tract. Their work aims to define better markers that predict how patients respond to treatments for inflammatory bowel disease. They leverage IBD genetics studies performed in the UK as well as the community of researchers studying genetic risks for ulcerative colitis to perform large association studies followed by functional analyses to assess how best to use virology data.
Overview
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is characterized by chronic inflammation of the digestive tract. Symptoms can include severe abdominal pain, diarrhea, fatigue, and weight loss. IBD affects over1.6 million people in the USAaccording to the Crohn’s and Colitis Foundation of America, and according to the National Reviews Gastroenterol & Hepatology, there are currently欧洲250万患者and rising incidences in newly industrialized countries in Africa, Asia, and South America. Diagnosis is challenging and often delayed, leading many patients to progress to advanced stages of the disease, requiring surgery. Increasing evidence indicates that genetic and microbial factors, combined with environmental and lifestyle factors including infections, antibiotics, and diet, likely impact the development of IBD.
如果我们可以通过使用现代技术评估个人的免疫和胃肠道健康状况来更好地诊断，治疗和预防IBD怎么办？
越来越多的假设是，健康和疾病的特征是一个人能够适应多种刺激或“压力源”的能力。因此，可以通过评估对压力源的反应来预测一个人的疾病风险。评估个人对压力源的反应可能会揭示出疾病的早期迹象，而疾病静止时无法识别。例子包括心脏应激测试，该测试可以测量心脏对锻炼诊断心脏病引起的外部压力的反应以及葡萄糖耐受性测试，葡萄糖耐受性测试可以测量人体在摄入葡萄糖溶液以诊断妊娠糖尿病后处理糖的能力。最终，我们可能能够通过常规衡量人们每天经历的压力源和刺激的反应来优化健康！
The goal of this QuickFire Challenge is to evaluate immune and gastrointestinal health and ultimately predict risk of IBD by assessing the response of the immune and gastrointestinal systems to challenges with stressors. If you have an idea for a product, technology, or methodology to investigate the response of the human immune and gastrointestinal systems to stressors, Janssen Research & Development is awarding up to $50,000 with possible mentorship opportunities to help make that idea a reality.
Criteria
Please note: These are preferred and not required criteria.
Proposals containing the following criteria are preferred, but are not required. Please keep in mind that no idea is too big or too early for consideration. Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation.
首选评估人类或使用人类样品的产品，技术和方法。但是，还鼓励了体内，体外或其他类型的模型系统。首选证明概念验证的建议。例如，表明对应激源的反应与特定表型相关的建议可以区分变化的健康状态，或者可以预测疾病的风险。
Examples
Please note that the following are meant to represent examples only. If you have an idea that falls outside of these examples, we strongly encourage you to apply!
Stressors/Stimuli
可能评估的压力源或刺激的示例包括但不限于：
- 饮食因素：越来越多的证据表明饮食可能有助于IBD的发展。寻求评估人类免疫和胃肠道系统适应饮食刺激挑战的能力的建议。
- 感染或微生物因素：证据表明病毒或细菌感染以及暴露于微生物刺激可能代表IBD的触发因素。寻求评估人类免疫和胃肠道系统适应感染或微生物刺激挑战的能力的建议。
- Other Environmental or Lifestyle Factors: Proposals for evaluating the response of the human immune and gastrointestinal systems to other types of stressors, for example, specific environmental or lifestyle stimuli associated with IBD, are also strongly encouraged.
Responses to Stressors/Stimuli
Examples of responses to stressors or stimuli that may be evaluated include but are not limited to:
- 肠道通透性和肠道屏障健康的度量
- 先天免疫系统功能，包括受过训练的免疫力
- 免疫耐受性的度量，包括口服耐受性
- 细胞应力反应
- T-cell exhaustion
强烈鼓励评估与IBD相关的其他类型反应的建议。
Why this challenge matters
一个重要的需要准确预测wh的存在o is at high risk of developing IBD so that safe interventions can be provided to prevent progression to clinical disease. Janssen Research & Development and Johnson & Johnson Innovation have a successful history in creating new markets, delivering breakthrough innovation and establishing strong partnerships built on a shared vision. We believe a good idea can come from anywhere, and it’s our goal to break through the noise of the crowded landscape and to accelerate the development of novel technologies, treatments, and pharmaceuticals to provide solutions to patients.
申请流程
Proposals should include: (1) definition of the stressor(s) to be applied; (2) definition of the human population or model system used to evaluate the response to the stressor; and (3) definition of how the response will be measured.
The goal of this QuickFire Challenge is to employ response to stressors in order to evaluate immune and gastrointestinal health and to ultimately predict risk of IBD. Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
• Potential to impact healthcare outcomes in a strategic area of interest
•解决方案的独特性和当前市场的竞争水平
•技术的质量和可行性
•团队信誉和能力
•计划的清晰度：里程碑和定义的GO/NO DO决定
Reward
- 最高50,000美元的赠款
- 访问约翰逊和约翰逊创新专家的网络
关于詹森制药，约翰逊和约翰逊公司
At the Janssen Pharmaceutical, Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.
We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at @JanssenGlobal.
About Johnson & Johnson Innovation, JLABS
ld乐动强生公司创新有限责任公司专注于加速rating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation, JLABS (JLABS), Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.
Johnson＆Johnson Innovation，JLABS（JLABS）是一个全球开放创新生态系统的网络，使和授权创新者能够为世界各地的患者创造和加速挽救生命，增强生命的健康和健康解决方案。JLABS通过为新兴公司提供最佳环境来实现这一点明天的突破性医疗解决方案。在JLABS，我们珍视伟大的想法，并热衷于消除成功的障碍，以帮助创新者释放其早期科学发现的潜力。JLABS是一个无弦的模型，这意味着企业家可以在坚持其知识产权的同时自由发展科学。JLABS向包括药品，医疗设备，消费者和数字健康部门在内的广泛医疗保健领域开放企业家。
jlabscurrently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe. For more information about JLABS, please visit www.www.2574design.com.